Navigation Links
Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
Date:10/20/2009

> Dr. Colin Goddard, Chief Executive Officer of OSI Pharmaceuticals added, "As a leading Chinese pharmaceutical company with a successful track record of developing and commercializing oncology products in China, we are confident that Simcere has the right capabilities and resources to successfully manufacture, develop and market OSI-930 in China. We are looking forward to working with Simcere on this exciting collaboration."

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells anti-infective medication, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "pr
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014  Hanger, Inc. (NYSE: ... report its results of operations for the quarter ended ... the market closes.  A conference call to discuss these ... on Friday, November 7, 2014. Those wishing to participate ... Friday, November 14, 2014 by dialing 1-855-859-2056 and referencing ...
(Date:10/17/2014)... 2014 Research and Markets  has ... Development Prospect of China Dialysis Market, 2014-2018" ... on the 2013 version, this update Report provides ... industry and the relevant effect in recent three ... segmentations. Moreover, it analyzes Chinese private-owned hemodialysis services. ...
(Date:10/17/2014)... -- Investor-Edge has initiated coverage on the ... ), NPS Pharmaceuticals Inc. (NASDAQ: NPSP ), ... Inc. (NASDAQ: MNTA ), and Catalyst Pharmaceutical ... companies can be accessed at: http://investor-edge.com/register . ... ended on a mixed note as the Dow Jones ...
Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5
... & Gamble Company (NYSE: PG ) today announced ... Advisory Panel (SEAP). The new members are: ... Dr. Howard Frumkin – Dean, School of the Public ... Former Secretary, California Environmental Protection Agency ...
... 2011 Following through with plans to expand its Medical ... Florida. Currently operating on a fee for service basis, OMI ... the state. IMD Companies anticipates that OMI will be servicing ... of time. ABOUT IMD COMPANIES, INC. ...
Cached Medicine Technology:P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 2P&G Welcomes New Members to U.S. Sustainability Expert Advisory Panel 3IMD Companies, Inc. Announces OMI Operations in Florida 2
(Date:10/20/2014)... 20, 2014 Do you ever feel ... comes a wonderful app Metassessor for teachers, specialists and ... helped its client “Intervention Development LLC” to launch ... is designed for iOS 4.3 or later and is ... is optimized for iPhone 5. It is now available ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
(Date:10/19/2014)... 2014 Visual Impact Frequency Training ... been released to the public generating a frenzied ... and fitness community. The commotion surrounding the program's ... Delmonico prompting an investigative review. , "Many gym-goers ... is commonly known as a training 'plateau' where ...
(Date:10/19/2014)... October 19, 2014 The federal ... continuing to move forward in Massachusetts federal court, ... filed over the dialysis medication, Bernstein Liebhard LLP ... October 15th shows 2,127 claims now filed over ... in the U.S. District Court, District of Massachusetts. ...
(Date:10/19/2014)... California (PRWEB) October 19, 2014 Theme and ... plugin for Final Cut Pro X entitled ProSketchy. ... looking text into any video project.” Said Christiana Austin, CEO ... needed to customize their own sketch style text.” , With ... smudged and smeared text all with in Final Cut Pro ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 3Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 4Health News:Announcing a New Plugin for Final Cut Pro X ProSketchy from Pixel Film Studios 2Health News:Announcing a New Plugin for Final Cut Pro X ProSketchy from Pixel Film Studios 3
... , ... ... , ... , , ...
... disease (HD) is a cruel, hereditary condition that leads to ... Currently, there are no treatments to slow down or ... although they do not show symptoms until late in life. ... of Neuroscience , Stephen Ferguson and Fabiola Ribeiro of Robarts ...
... ... supplements has created a brand new market for health supplements, customers who want to ... attention, HGH Supplements like Sytropin. , ... (PRWEB) February 23, 2010 -- Increased positive coverage by respected media ...
... , ... ... ... ...
... ... ... ... ...
... The George Washington University, School of Public Health and Health ... chronic disease, is on the rise in America and released ... surging cost of treatment, and the more than 1 million ... from GW, Changing pO2licy: The Elements for Improving Childhood Asthma ...
Cached Medicine News:Health News:Catholic Health Association Statement on February 25 Health Reform Summit 2Health News:Catholic Health Association Statement on February 25 Health Reform Summit 3Health News:Protecting the brain from a deadly genetic disease 2Health News:Sytropin HGH Shows Promising Anti-Aging Results 2Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Health News:Diabetics Twice as Likely to Have Hearing Loss; Massachusetts HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 2Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 3Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 4Health News:Global Hospitals and Healthcare Suppliers Focus on Cutting Costs and Improving Quality at 2010 GHX Supply Chain Summit 5Health News:Startling new childhood asthma data 2Health News:Startling new childhood asthma data 3Health News:Startling new childhood asthma data 4
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 24 gage needle stick is desired....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used for the introduction of catheters, balloons and other vascular devices....
Medicine Products: